STOCK TITAN

Palisade Bio Inc - PALI STOCK NEWS

Welcome to our dedicated news page for Palisade Bio (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palisade Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palisade Bio's position in the market.

Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life Sciences to advance precision medicine for ulcerative colitis therapy. The partnership grants Palisade Bio access to advanced bioinformatics tools for understanding complex disease pathways and predicting responses to PDE4 inhibitors. Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1600 UC patient samples to identify biomarkers for patient selection using machine learning. This collaboration marks a significant milestone in Palisade Bio's mission to redefine UC treatment through personalized therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.08%
Tags
none
-
Rhea-AI Summary
Palisade Bio successfully demonstrates bioactivation of PALI-2108 in an ex-vivo study of normal healthy and ulcerative colitis patients' stool, showing promising results for the treatment of ulcerative colitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.55%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. (PALI) to present at the Virtual Investor Lunch Break event, featuring an overview by CEO J.D. Finley and CMO Dr. Mitch Jones. The live webcast on April 16, 2024, will focus on the company's business outlook and opportunities in autoimmune, inflammatory, and fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
conferences
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announces the advancement of PALI-2108, a treatment for moderate-to-severe ulcerative colitis, towards Phase 1 clinical study by the end of the year. The company presented at IBD Innovate, discussing the development, differentiation, and clinical pathway of PALI-2108.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.91%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announces a 1-for-15 reverse stock split to increase per share trading price and comply with Nasdaq listing requirements. The split will be effective on April 5, 2024, with trading under the symbol 'PALI' and new CUSIP number 696389402.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary
Palisade Bio, Inc. (PALI) progresses PALI-2108 towards Phase 1 clinical study for ulcerative colitis treatment, forms Clinical Advisory Board, and reports financial results for 2023. The company has sufficient cash to achieve milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
Rhea-AI Summary
Palisade Bio, Inc. (PALI) announces acceptance of abstract for poster presentation at DDW 2024 for their novel therapeutic PALI-2108 for ulcerative colitis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Summary
Palisade Bio, Inc. announces a strategic streamlining of the Board to align with current clinical development and corporate vision. The company is advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis towards a Phase 1 clinical study, with significant progress in various areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. issued a correction to its press release, clarifying the timeline for the PALI-2108 Phase 1 clinical study. The original release incorrectly stated that the study was on track to commence next year, while the company reiterates that it is set to launch in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) has appointed two renowned gastroenterologists, Dr. Bruce Sands and Dr. Florian Rieder, to its Clinical Advisory Board (CAB) to advise on the development of novel therapeutics for serious chronic gastrointestinal diseases, with a focus on Inflammatory Bowel Disease (IBD). The company's lead asset PALI-2108 for the treatment of ulcerative colitis is on track for a Phase 1 clinical study launch next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Palisade Bio Inc

Nasdaq:PALI

PALI Rankings

PALI Stock Data

3.51M
836.48k
1.75%
15.52%
0.21%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Germantown